PBM (Psyence Biomedical) Total Equity: $16.94 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBM Psyence Biomedical Ltd PBM
14 GF Score
Price $5.40
! 4 Warning Signs
View Full Analysis

What is Psyence Biomedical Total Equity?

Psyence Biomedical PBM +9.64% 14 Total Equity is $16.94 Mil as of Mar. 2026. GuruFocus rates PBM with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Psyence Biomedical's total equity for the quarter that ended in Mar. 2026 was $16.94 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Psyence Biomedical Total Equity Historical Data

* Premium members only.

The historical data trend for Psyence Biomedical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Psyence Biomedical Total Equity Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial 1.70 -0.20 -10.97 6.72 16.94

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.97 -1.26 6.72 11.87 16.94
PBM
14GF Score
Psyence Biomedical Ltd PBM
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Psyence Biomedical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Psyence Biomedical's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=17.567-0.623
=16.94

Psyence Biomedical's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=17.567-0.623
=16.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $16.94 Mil mean?
Psyence Biomedical (PBM) has a Total Equity of $16.94 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Psyence Biomedical and its competitors.
Is Psyence Biomedical's Total Equity too high?
Psyence Biomedical's current Total Equity is $16.94 Mil. Overall, Psyence Biomedical has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Psyence Biomedical's Total Equity compare to NRSN and PLUR?
Psyence Biomedical's Total Equity of $16.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Psyence Biomedical and its competitors. Psyence Biomedical's current Total Equity is $16.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psyence Biomedical stock overvalued right now?
Psyence Biomedical (PBM) has a current Total Equity of $16.94 Mil. The current Total Equity is $16.94 Mil. Psyence Biomedical's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Psyence Biomedical (PBM), the current Total Equity is $16.94 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Psyence Biomedical Business Description

Address 121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
14GF Score

Get the complete analysis for PBM

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.40
Price